Authors: de Man, FHAF Jonkers, IJAM Schwedhelm, E Smelt, AHM Onkenhout, W van Duyvenvoorde, W Buytenhek, R Leuven, JAG Troost, R van der Laarse, A Princen, HMG

Citation: Fhaf. De Man et al., Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia - Effects of bezafibrate therapy, ART THROM V, 20(11), 2000, pp. 2434-2440

Authors: de Man, FHAF de Beer, F van der Laarse, A Jansen, H Leuven, JAG Souverijn, JHM Vroom, TFFP Schoormans, SCM Fruchart, JC Havekes, LM Smelt, AHM

Citation: Fhaf. De Man et al., The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia ismediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding, ATHEROSCLER, 153(2), 2000, pp. 363-371

Authors: Mohrschladt, MF Weverling-Rijnsburger, AWE de Man, FHAF Stoeken, DJ Sturk, A Smelt, AHM Westendorp, RGJ

Citation: Mf. Mohrschladt et al., Hyperlipoproteinemia affects cytokine production in whole blood samples exvivo. The influence of lipid-lowering therapy, ATHEROSCLER, 148(2), 2000, pp. 413-419

Authors: Jonkers, IJAM de Man, FHAF Onkenhout, W van der Laarse, A Smelt, AHM

Citation: Ijam. Jonkers et al., Implication of fibrate therapy for homocysteine, LANCET, 354(9185), 1999, pp. 1208-1208